MedTrace Logo

Lorcaserin Intra Venous Cocaine Effects

NCT02680288 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2016-03-18

No results posted yet for this study

Summary

This is a randomized, cross-over, single-blind, placebo-controlled, single-center, multiple-panel evaluation of the potential for oral lorcaserin to modify cocaine self-administration in a laboratory setting. To prevent unauthorized drug use, study medications will be administered as participants are confined during overnight stays at the Medical Center. Non-treatment-seeking, regular cocaine users will receive oral treatment with single doses of placebo, lorcaserin 10 mg (Panel 1), or lorcaserin 20 mg (Panel 2). Afterwards, the subjective and reinforcing effects of intravenous cocaine will be measured in a laboratory setting.

Conditions

  • Cocaine Use Disorders

Interventions

DRUG

Lorcaserin, 10 mg

Oral type 2C serotonergic agonist, low-dose

DRUG

Lorcaserin, 20 mg

Oral type 2C serotonergic agonist, high-dose

OTHER

Oral Placebo

Oral inert treatment

Sponsors & Collaborators

  • Midwest Biomedical Research Foundation

    lead OTHER

Principal Investigators

  • Kenneth W Grasing, MD · Midwest Biomedical Research Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-09-30
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680288 on ClinicalTrials.gov